-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
MM3122
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/2574390-27-3.gif)
| Category | SARS-CoV |
| CAS | 2574390-27-3 |
| Description | MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells. |
Product Information
| Synonyms | MM3122|Ac-GQFR-kbt|GTPL11533|EX-A6891|compound 4 [Mahoney et al, 2021]|MM-3122|(2S)-N-[(1S)-1-{[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl}-2-phenylethyl]-2-(2-acetamidoacetamido)pentanediamide|2574390-27-3 |
| Molecular Weight | 665.76 |
| Molecular Formula | C31H39N9O6S |
| Canonical SMILES | CC(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2 |
| Purity | ≥98% (HPLC) |
| Solubility | DMSO:90 mg/mL (135.2 mM), Need ultrasonic |
| Appearance | Solid powder |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 1140 |
| Exact Mass | 665.27440117 |
| In Vitro | MM3122 (0-1 μM) has inhibitory activity against HGFA, matriptase, hepsin and thrombin with the IC50 values of 32, 0.31, 0.19 and more than 20 nM, respectively. MM3122 (0.1-100 μM) inhibits SARS-CoV-2 calu-3, VSV-SARS CoV-2 chimera calu-3 and MERS VSV pseudotype calu-3 with the EC50 values of 74, 0.43 and 0.87 nM, respectively. |
| In Vivo | MM3122 (i.p., 0-100 mg/kg, daily, 7 days) has no adverse effects, no weight loss or changes in harvested organs (liver, spleen and kidney) compared to controls in NOD-scid IL2Rgnull (NSG) mice. MM3122 (i.p., 16.7 mg/kg, once) has a half-life of 8.6 hours in plasma and 7.5 hours in lung of NSG mice. |
| Target | SARS-CoV |
| XLogP3-AA | 0.2 |
Description of First Aid Measures
Eye contact
Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.
Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.
InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.
IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.